Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

William Arcese for the Rome Transplant Network

Research output: Contribution to journalArticle

Abstract

In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40-91%) and 54% (95% CI 33-86%), 40% (95% CI 22-74%), and 34% (95% CI 16-68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.

Original languageEnglish
Pages (from-to)1041-1048
Number of pages8
JournalAnnals of Hematology
Volume97
Issue number6
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Cutaneous T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Tissue Donors
Lymphocytes
Transplants
Unrelated Donors
Survival
Fetal Blood
Siblings
Lymphoma
Retrospective Studies
Recurrence
Drug Therapy
Mortality

Keywords

  • Adult
  • Aged
  • Cancer Care Facilities
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Graft vs Host Disease/epidemiology
  • Graft vs Tumor Effect
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Humans
  • Incidence
  • Italy/epidemiology
  • Lymphoma, T-Cell, Cutaneous/epidemiology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Remission Induction
  • Retrospective Studies
  • Risk
  • Secondary Prevention
  • Severity of Illness Index
  • Survival Analysis
  • Transplantation, Homologous/adverse effects
  • Young Adult

Cite this

Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. / William Arcese for the Rome Transplant Network.

In: Annals of Hematology, Vol. 97, No. 6, 06.2018, p. 1041-1048.

Research output: Contribution to journalArticle

William Arcese for the Rome Transplant Network. / Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma. In: Annals of Hematology. 2018 ; Vol. 97, No. 6. pp. 1041-1048.
@article{8cf30f7e577449998ec14c317a6e461c,
title = "Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma",
abstract = "In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5{\%}) were in complete remission (CR), nine (56.3{\%}) in partial remission (PR), and five (31.2{\%}) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61{\%} (95{\%} CI 40-91{\%}) and 54{\%} (95{\%} CI 33-86{\%}), 40{\%} (95{\%} CI 22-74{\%}), and 34{\%} (95{\%} CI 16-68{\%}), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.",
keywords = "Adult, Aged, Cancer Care Facilities, Cohort Studies, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease/epidemiology, Graft vs Tumor Effect, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Incidence, Italy/epidemiology, Lymphoma, T-Cell, Cutaneous/epidemiology, Male, Middle Aged, Neoplasm Staging, Remission Induction, Retrospective Studies, Risk, Secondary Prevention, Severity of Illness Index, Survival Analysis, Transplantation, Homologous/adverse effects, Young Adult",
author = "{William Arcese for the Rome Transplant Network} and Laura Cudillo and Raffaella Cerretti and Alessandra Picardi and Benedetta Mariotti and {De Angelis}, Gottardo and Maria Cantonetti and Massimiliano Postorino and Eleonora Ceresoli and {De Santis}, Giovanna and Daniela Nasso and Francesco Pisani and Enrico Scala and {Di Piazza}, Fabio and Alessandro Lanti",
year = "2018",
month = "6",
doi = "10.1007/s00277-018-3275-z",
language = "English",
volume = "97",
pages = "1041--1048",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

AU - William Arcese for the Rome Transplant Network

AU - Cudillo, Laura

AU - Cerretti, Raffaella

AU - Picardi, Alessandra

AU - Mariotti, Benedetta

AU - De Angelis, Gottardo

AU - Cantonetti, Maria

AU - Postorino, Massimiliano

AU - Ceresoli, Eleonora

AU - De Santis, Giovanna

AU - Nasso, Daniela

AU - Pisani, Francesco

AU - Scala, Enrico

AU - Di Piazza, Fabio

AU - Lanti, Alessandro

PY - 2018/6

Y1 - 2018/6

N2 - In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40-91%) and 54% (95% CI 33-86%), 40% (95% CI 22-74%), and 34% (95% CI 16-68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.

AB - In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6-130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40-91%) and 54% (95% CI 33-86%), 40% (95% CI 22-74%), and 34% (95% CI 16-68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.

KW - Adult

KW - Aged

KW - Cancer Care Facilities

KW - Cohort Studies

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Graft vs Host Disease/epidemiology

KW - Graft vs Tumor Effect

KW - Hematopoietic Stem Cell Transplantation/adverse effects

KW - Humans

KW - Incidence

KW - Italy/epidemiology

KW - Lymphoma, T-Cell, Cutaneous/epidemiology

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Remission Induction

KW - Retrospective Studies

KW - Risk

KW - Secondary Prevention

KW - Severity of Illness Index

KW - Survival Analysis

KW - Transplantation, Homologous/adverse effects

KW - Young Adult

U2 - 10.1007/s00277-018-3275-z

DO - 10.1007/s00277-018-3275-z

M3 - Article

C2 - 29442161

VL - 97

SP - 1041

EP - 1048

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 6

ER -